The Europe Lung Cancer Therapeutics Market size is estimated to worth USD 2.43 billion by 2026 from USD 1.78 billion in 2021, registering a CAGR of 6.47% during the forecast period. Europe is the second-largest region for the lung cancer therapeutics market.
Lung cancer diagnoses have grown due to increasing cancer awareness and introducing new medical diagnostic equipment and advanced therapies, driving the lung cancer therapeutics market forward in Europe. Lung cancer is a kind of cancer that develops in the tissues of the lungs. It's also known as pulmonary carcinoma, and it's characterized by uncontrolled lung tissue development. The expanding elderly population, changing lifestyles, and rising tobacco smoking, including passive smoking, are all likely drivers for the European lung cancer therapeutics market. Furthermore, factors such as focused and ground-breaking medication delivery to the lungs and the growing acceptance of customized therapies are viewed as key contributors driving the overall market of Europe Lung cancer therapeutics.
Lung cancer is becoming more common due to increased financing for the development of new medicines, increased pollution due to fast industrialization, and increased smokers. As a result, all of these factors have contributed to the Europe Lung cancer therapeutics market's expansion. The entire market has grown as the expense of cancer therapy has increased, as has the price of drugs. Furthermore, significant investments in development have aided the development of cancer treatments. Additionally, favorable government regulations for cancer treatments, as well as an increase in cancer prevalence, have fueled Europe's Lung cancer therapeutics market development.
The restricted treatment choices, widespread availability of generic critical medicines, and the large unmet need for diagnostics are expected to be the key factors limiting the Europe Lung cancer therapeutics market's growth. In addition, the market's growth has been stifled by the adverse effects of therapeutic interventions, side effects in the future, and the high cost of the therapies.
Adverse effects from radiation and chemotherapies are also a primary challenge. The expiration of patents on current drugs may have a negative influence on the industry. As a result, the industry's key companies must focus on safer medicines and innovative remedies.
This research report on the Europe Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:
By Treatment Type:
By Country:
Regionally, U.K is the leading market due to a high population base suffering from lung cancer, while Germany is anticipated to witness high growth in the forecast period. Europe is anticipated to be the second biggest market for lung cancer treatments due to significant government funding in the research and development of novel drugs, rising regulatory approvals, and technical advances in the area of cancer. In addition, increased adoption of advanced lung cancer treatments and rising lung cancer prevalence and diagnosis are anticipated to fuel growth in the area. One of the most important driving reasons for the growth of the lung cancer therapeutics market is the rising acceptance and demand for targeted treatments, which is considered to be the basis of precision medicine due to increased R&D activities. Other factors contributing to Europe's growing cancer rates include poor lifestyles and inappropriate diets, obesity, and a lack of physical activity. As a result, throughout the forecast period, the rising incidence and prevalence of cancer would likely fuel the expansion of the cancer treatments market in Europe.
KEY MARKET PLAYERS:
A few of the notable companies operating in the Europe Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Cisplatin
5.1.1.2 Taxol
5.1.1.3 Navelbine
5.1.1.4 Camptosar
5.1.1.5 Alimta
5.1.2 Radiotherapy
5.1.2.1 External Beam
5.1.2.2 Internal Beam
5.1.2.3 Systemic
5.1.3 Other Drugs
5.1.3.1 Abraxane
5.1.3.2 Avastin
5.1.3.3 Crizotinib
5.1.3.4 Docetaxel
5.1.3.5 Gefitinib
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 BoehringerIngelheim GmbH
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hoffman-La Roche
8.3 Pfizer Inc.
8.4 GlaxoSmitKline
8.5 Eli Lilly and Company
8.6 AstrazenecaPlc
8.7 Sanofi-Aventis
8.8 Agennix AG
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
